Arca
Skip to content
Tools
Tools

NGF: Beta-nerve growth factor

Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems.

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on NGF, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3
  • Other 2

Approved0

    Phase 33

    • Fasinumab
    • Fulranumab
    • Tanezumab

    Phase 20

      Phase 12

      • MEDI-578
      • PG-110

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Beta-nerve growth factor inhibitor.
      FasinumabPhase 3RegeneronAntibodyInhibitor0
      FulranumabPhase 3AmgenAntibodyInhibitor0
      TanezumabPhase 3PfizerAntibodyInhibitor0
      MEDI-578Phase 1AstraZeneca PharmaceuticalsOtherInhibitor0
      PG-110Phase 1Abbott LaboratoriesOtherInhibitor0

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Hereditary sensory and autonomic neuropathy type 50.77
      • Osteoarthritis, knee0.56
      • Hypertensive disorder0.54
      • Pain0.52
      • Spinal stenosis0.51
      • Osteoarthritis, hip0.49
      • Coronary artery disorder0.47
      • Total joint arthroplasty0.41

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1649058, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01138, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.